聚集相关企业300余家，机器人产业链规模超百亿元……北京亦庄，为何扎堆这么多机器人企业？ 企业"用脚投票"，政策是首要吸引力。2025年8月，亦庄发布"具身智能机器人十条"：每年发1亿元"数据券"、 以"打样券"降成本、给人形机器人销售补贴……条条硬核，覆盖数据、场景、研发、销售全链条。 更关键的是场景。2025年2月，一份特殊的招聘启事——"北京亦庄机器人九大标杆场景机会清单"，由机器人"天 工"发布：正式全面开放亦庄新城场景资源，在两年内释放超万台、近50亿元具身智能机器人应用机会，其中超千 台为人形机器人需求。 场景开放不止于清单。蔡继征介绍，以亦庄新城为载体，亦庄正在实施具身智能社会实验计划，让机器人在真实 世界里学习。"目前已开放超市、药房、酒店、仓库等超过40个真实场景，形成一批百万级高质量自主具身智能数 据集。" 挂牌北京市唯一的类人机器人未来产业育新基地，建设北京市首个机器人柔性敏捷制造平台，落地北京市首个人 形机器人中试验证平台，布局25万平方米的北京市机器人产业园，支持百亿机器人产业基金落地，打造具身智能 机器人4S店……搭平台、聚要素、建生态，亦庄已基本形成了覆盖核心零部件、整机制造、系 ...

Core Viewpoint - The strategic investment by Hangzhou Kelin Electric Co., Ltd. in Shanghai Kepler Robotics Co., Ltd. marks a significant step towards deep industrial collaboration, focusing on the large-scale application of embodied intelligence technology in industrial scenarios [2][3]. Group 1: Strategic Investment and Collaboration - The investment amounts to a billion-level financing, with Hangzhou Kelin acquiring approximately 10% equity in Kepler [2]. - This partnership aims to establish a long-term, stable, and multi-dimensional cooperation mechanism, enhancing supply chain collaboration, business scenario implementation, and capital cooperation [2][3]. - Both companies emphasize the importance of this investment for future industrial synergy, technology co-development, and market expansion [3]. Group 2: Technological Framework - Kepler has developed a comprehensive embodied intelligence technology system that integrates "intelligent brain" and "industrial-grade hardware," supporting stable operations of humanoid and special robots in high-intensity industrial environments [4]. - The core of the intelligent system is the self-developed layered model VLA+, which facilitates multi-modal interaction and decision-making, enabling robots to perform tasks in complex environments [4]. - The VLA+ model employs a dual-engine learning mechanism, combining simulation and real-world data to enhance decision-making capabilities and ensure controllable, verifiable, and replicable embodied decisions [4]. Group 3: Hardware Capabilities - Kepler's hardware is designed for high-intensity industrial and special operations, featuring a long-lasting operational capacity of 8 hours after a 1-hour charge [5]. - The core execution system utilizes a self-developed planetary roller screw actuator, achieving significant breakthroughs in key performance indicators such as high load, low backlash, and longevity [5]. - The integration of the execution system with the VLA+ intelligent architecture allows for precise and reliable physical actions based on algorithmic capabilities [5]. Group 4: Collaborative Efforts - The collaboration will focus on key aspects of the industrial chain, with Hangzhou Kelin providing high-quality electrical components and manufacturing systems to enhance hardware reliability and delivery efficiency [7]. - Kepler's products will benefit from Kelin's customer resources and channel advantages in the power grid, new energy, and industrial sectors, facilitating more efficient market entry [7]. - The partnership aims to create a one-stop service that integrates Kepler's technological capabilities into Kelin's overall solution framework [7]. Group 5: Long-term Growth Potential - The equity investment establishes a solid capital bond and provides institutional support for long-term collaborative development [9]. - Future cooperation may explore joint ventures, technology acquisitions, and industrial funds, enhancing the integration of embodied intelligence technology into real industrial applications [9]. - This strategic investment signifies Kepler's transition into a new development phase centered on "industrial-grade implementation," with ongoing collaboration expected to accelerate the smart upgrade of the industry [9].

通知 | 关于举办"2026大湾区工业具身智能大会"的通知 近日， 口腔手术机器人公司 上海央山医疗科技有限公司（以下简称：央山医疗） 完成数千万元人民币 pre A轮融资。本轮融资由医疗专业投资机构 山蓝资本、远毅资本 联合领投，知名早期科技投资机构 蓝 驰创投 作为公司原有股东持续加码跟投。 领投,知名早期科技投资机 构蓝驰创投作为公司原有股 东持续加码跟投。 F INVESTMENT L A N T INSTITUTION ▶▶▶ 山蓝资本、远毅资本、蓝驰创投 DID牙种植牵引器 国家局创新医疗器械特别审查程序 管理局医疗器械技术审评中心 山蓝资本 YANGSHAN MEDICAL RAISES PRE-A ROUND 投资总监杭元恺表示: 医疗手术机器人赛道正迎来技术落地与需求 释放的双重红利。央山医疗在核心导航技术 研发与产品口腔场景适配方面构建了鲜明壁 垒、其产品在口腔种植手术中展现出的高效 性与稳定性令人印象深刻。我们看好公司团 队扎实的技术沉淀与清晰的商业化路径，期 待通过本次投资、助力公司加速市场渗透、 推动口腔行业数智化升级。 近教资本 董事总经理唐轶男訓为: 机器人技术正在推动口腔种植进 ...

以下文章来源于人形机器人场景应用联盟 ，作者编辑部 根据人形机器人场景应用联盟不完全统计， 2026年1月， 共有 超19个 人形机器人相关公开中标项目公 告，披露中标总金额 约5500万人民币 。 （不包括面向K12教育的小型桌面设备机器人，不包括基地及实 验室工程建设项目） | 采购单位 | 项目名称 | 中标单位 | 中标金额(元) | 标的物/标书内容 | 公示时间 | | --- | --- | --- | --- | --- | --- | | 中国铁塔股份有限 | 中国铁塔2025年机器人机器狗等无人 | 宁波工业互联网研 | | | | | 公司 | 智能终端设备采购项目 (标包2: 人形 | 究院有限公司 | 505110 | 人形机器人 | 2026/1/4 | | | 机器人）第三次成交结果公示 | | | | | | 江西师范大学 | 工业机器人采购项目 (采购编号: JXGZ2025-12-1304) 电子化政府采 | 杭州鑫柳树机器人 | 671800 | 宇树 Go2 Edu/G1Edu | 2026/1/4 | | | | 科技有限公司 | | 基础版/G1 Edu进阶版 | ...

Core Viewpoint - Deep Intelligence has completed a new round of financing amounting to $60 million, with total funding exceeding $100 million in just two months, indicating strong investor confidence in its AI-driven drug development capabilities [2][3]. Group 1: Financing and Investment - The new investors in this financing round include Xincheng Capital, Jinyi Capital, and KAITAI Capital, while existing shareholders such as Dinghui Baifu and New Ding Capital have also increased their stakes [2]. - The funds raised will primarily be used for upgrading the core technology system of the company [2]. Group 2: Technological Advancements - Deep Intelligence offers a full-stack intelligent solution for global pharmaceutical companies, covering all stages from preclinical research to post-marketing studies, unlike most companies that focus only on the preclinical phase [2][3]. - The company has achieved a breakthrough in its underlying technology architecture, which has contributed to its ability to attract continuous investment [3]. Group 3: AI Implementation in Drug Development - The company has developed a "bionic brain" composed of high-precision "Atomic Agents" that handle various tasks in the clinical research process, such as protocol design, statistical analysis, and regulatory compliance [4]. - The "bionic brain" operates through a closed-loop process of hypothesis-verification-reflection-correction, achieving an accuracy rate of over 99% in medical terminology [4][5]. Group 4: Self-Improving AI Systems - The system can automatically trigger reflection processes for attribution analysis, source tracing, and self-revision, allowing it to correct its own issues over time [5]. - Deep Intelligence has implemented a four-layer protective mechanism to address hallucination issues in AI models, achieving an industrial-grade accuracy of 99.9% [5]. Group 5: Innovations in Clinical Trials - The company has introduced a new Protocol Rehearsal AI that simulates virtual clinical trials to predict enrollment rates, dropout risks, and resource bottlenecks before actual patient recruitment [5]. - This innovation aims to accelerate the application of AI technology in human clinical trials, transforming drug development from a labor-intensive process to one focused on intelligent decision-making [5].

通知 | 关于举办"2026大湾区工业具身智能大会"的通知 近日，卓世科技（海南）股份有限公司（以下简称：卓世科技）完成Pre-IPO轮数亿元融资，本轮融资由 国泰君安创新投、优必选科技、国新国证投资、浙江华宇等共同投资。此次融资将主要用于加大在行业大 模型及智能体领域的研发投入、继续拓展行业场景落地应用，推动行业大模型在具身智能机器人领域"通 用大脑"等前沿领域的协同创新，进一步夯实卓世科技在行业大模型领域的领先地位。 商务合作 商务活动｜宣传推广｜转载开白等 联系电话｜18355423366 END 卓世科技凭借卓越的技术实力，获得国家网信办首批大模型+深度学习算法双备案资质、国家级专精特新 重点"小巨人"、国家高新技术企业等权威认可，累计斩获百余项人工智能大模型发明专利，业务全面覆盖 模型训练及推理、工具平台开发、行业应用开发等全链条服务，为各行业提供从模型大脑到智能应用和智 能终端为一体化的AI解决方案。 卓世科技创始人兼CEO屠静表示："本轮融资的成功，特别是与知名投行、机器人头部企业、行业客户等 战略伙伴的深度绑定，标志着公司已经从拥有产品技术优势的行业大摸型开始走向规模化产业赋能的关键 转折。我 ...

Core Insights - The company "知有无界" has successfully completed nearly 20 million yuan in angel round financing, with total financing approaching 50 million yuan [1] - The angel round was exclusively invested by Songhe Venture Capital, which is recognized for its role in promoting technological innovation and entrepreneurship in China [1] - The rapid growth of the company is notable, having completed three rounds of financing within four months since its establishment [1] Financing Details - The company secured over 10 million yuan in seed and seed+ rounds from investors including Zhuoyuan Asia, Lihua Science and Technology, and Chuhui Capital [1] - The successful completion of the angel round further validates the market's recognition of the company's technological capabilities and strategic business development [1] Leadership and Expertise - The founder and CEO, Dr. Guo Guanqu, is a Tsinghua University graduate specializing in robotics control and algorithms, with over 10 published papers and patents [1] - The chief scientist and co-founder, Professor Wang Xueqian, is a Tsinghua University professor and national expert, recognized for his contributions to robotics dynamics and control [4] Product and Technology Strategy - The company focuses on industrial scenarios, aiming to create a series of general-purpose industrial robots for applications such as ship spraying, cleaning, and container handling [6] - The technology framework includes a cloud-based multimodal large model and a MOE multi-expert industrial scene model, combined with proprietary robotic hardware for comprehensive capability output [6] - Key products like "愚公1号" and "马良X1" have been launched, aligning closely with frontline industrial applications and establishing partnerships with leading industry clients [6]

Core Insights - The article highlights the completion of nearly 100 million RMB Pre-A+ round financing by Shanghai Zhuoyide Robotics, aimed at enhancing the development of humanoid robots and emotional value services, particularly in elder care and companionship [1][4]. Financing and Strategic Partnerships - The financing round was led by Shanghai Pudong Leading Area Investment Center and Shanghai Zhangjiang Technology Venture Capital, with participation from various institutions, including strategic investors like Qingdao Zhenghe Industrial Co., Ltd. and Xiamen Songlin Technology Co., Ltd. [1][15]. - The involvement of industry capital signifies a crucial empowerment for Zhuoyide's vision of "emotional intelligence" in robotics, with partners contributing to both the physical and application aspects of the robots [15][16]. Product Development and Technological Advancements - Zhuoyide Robotics has introduced a diversified product matrix, including: - Moya, the world's first fully embodied intelligent bionic robot, designed for emotional companionship and elder care [5]. - Xueba 01, a robot PhD IP developed in collaboration with Shanghai Theatre Academy and Shanghai University of Technology, focusing on knowledge output and artistic expression [7]. - X3B, a general-purpose humanoid robot platform capable of executing complex movements and tasks across various industries [9]. - The company emphasizes the integration of advanced technologies, such as cross-modal perception and emotional computing, to enhance the robots' interaction capabilities and emotional intelligence [12]. Market Focus and Applications - The financing will focus on three core areas: - Deepening core technology and product iterations to enhance emotional interaction and adaptability [19]. - Upgrading mass production and supply chain systems to ensure product reliability and consistency, with over 1,000 intention orders already secured [20]. - Promoting ecosystem collaboration and market penetration, particularly in the elder care sector [21]. Company Milestones and Future Directions - Zhuoyide Robotics recently celebrated its headquarters relocation and the opening of a new exhibition hall, marking a significant milestone in its operational scale and research capabilities [21]. - The company aims to establish a comprehensive product ecosystem and clarify its commercialization path, entering a new phase of scaled and market-oriented development [21].

Core Viewpoint - Guangzhou Deep Medical Instrument Technology Co., Ltd. has completed its Series A financing, indicating strong interest from medical investment funds in the field of microscope surgical robots and recognition of the company's unique technology and execution capabilities [1][3]. Group 1: Company Overview - Deep Medical is a founding member of the Microsurgery Branch of the China Medical Device Industry Association, focusing on intelligent devices for all aspects of microscope surgery [3][17]. - The flagship product, FUNZAR microscope surgical robot, has been recognized as a significant advancement in microsurgery for two consecutive years (2024/2025) and was ranked first among the top five advancements in 2025 [3][17]. Group 2: Technological Innovation - FUNZAR is the world's first modular universal microscope surgical robot system, aiming to redefine the standards of microscope surgery with its innovative design [8][9]. - The system features hand-eye integration with a magnification capability of 10-100 times, allowing surgeons to operate with precision [8]. - FUNZAR employs a modular design with multiple robotic arms, enabling autonomous operations without the need for assistant surgeons [9][10]. Group 3: Clinical Progress - Since its official operation in April 2024, Deep Medical has rapidly progressed through product development, animal testing, and clinical trials, achieving the first clinical enrollment in December 2024 [12]. - Clinical trials for FUNZAR are currently underway in top hospitals across Beijing, Shanghai, Changsha, and Guangzhou, demonstrating its technical advantages and stability [12]. Group 4: Investment and Support - The company has received continuous support from investors like Wanfu Chuanggu and Kangjun Capital, who recognize the strategic value of universal microscope surgical robots [13][14]. - Kangjun Capital emphasizes the innovative technology and execution capabilities of the team, highlighting the potential for FUNZAR to address clinical challenges in microsurgery [14][16].

| 融资方 | 国别 | 公开日期 | 融资轮次 | 融资金额 | 投资方 | | --- | --- | --- | --- | --- | --- | | 墨甲机器人 | 中国 | 2026/1/1 | 天使轮 | 1亿元人民币 | IDG资本、芜湖投资集团、智元机器人、伯特利、富 | | | | | | | 春染织、芜湖经济技术开发区伟达创业投资有限公司 | | 具脑磐石 | 中国 | 2026/1/4 | 种子轮 | 数千万元人民币 | 东方精工, 乐聚机器人, 道禾投资, 四川科创投集团 | | 无穹创新 | 中国 | 2026/1/4 | Pre-A轮 | 数千万元人民币 | XBOTPARK基金、元不原点、晨晖创投、知行研习院 | | 智身科技 | 中国 | 2026/1/4 | A轮 | 数亿元人民币 | 蒙鹏科技,贵安鲲鹏基金,金马游乐,智元机器人, | | | | | | | 时代伯乐 | | 逐际动力 | 中国 | 2026/1/6 | A+轮 | / | 东方富海，天创资本，基石资本，光洋股份，东土科 | | | | | | | 技, 宏叡投资, 湖南财鑫集团, 中鼎集团 | | 强脑 ...